33.25
1.62%
0.53
Collegium Pharmaceutical Inc stock is traded at $33.25, with a volume of 105.52K.
It is up +1.62% in the last 24 hours and down -20.57% over the past month.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
See More
Previous Close:
$32.72
Open:
$32.6
24h Volume:
105.52K
Relative Volume:
0.30
Market Cap:
$1.05B
Revenue:
$566.77M
Net Income/Loss:
$48.16M
P/E Ratio:
-89.86
EPS:
-0.37
Net Cash Flow:
$274.29M
1W Performance:
-5.65%
1M Performance:
-20.57%
6M Performance:
-11.36%
1Y Performance:
+49.77%
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Name
Collegium Pharmaceutical Inc
Sector
Phone
781-713-3699
Address
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-04-24 | Downgrade | Jefferies | Buy → Hold |
Aug-25-23 | Reiterated | Needham | Buy |
May-02-23 | Resumed | Jefferies | Buy |
Aug-08-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
Feb-15-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Aug-06-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
Jul-14-20 | Initiated | BWS Financial | Sell |
May-27-20 | Initiated | Guggenheim | Neutral |
Feb-19-20 | Resumed | Jefferies | Buy |
Oct-30-19 | Reiterated | Needham | Buy |
May-03-19 | Resumed | H.C. Wainwright | Buy |
Apr-12-19 | Resumed | Janney | Buy |
Mar-20-19 | Initiated | SunTrust | Hold |
Jan-16-19 | Reiterated | Needham | Buy |
Mar-08-18 | Reiterated | H.C. Wainwright | Buy |
Feb-07-18 | Reiterated | Needham | Buy |
Dec-05-17 | Reiterated | Needham | Buy |
Sep-11-17 | Initiated | H.C. Wainwright | Buy |
May-11-17 | Reiterated | Needham | Buy |
Sep-13-16 | Initiated | Gabelli & Co | Buy |
Jun-01-15 | Initiated | Jefferies | Buy |
Jun-01-15 | Initiated | Needham | Buy |
Jun-01-15 | Initiated | Piper Jaffray | Overweight |
View All
Collegium Pharmaceutical Inc Stock (COLL) Latest News
Collegium Pharmaceutical is Now Oversold (COLL) - Nasdaq
Emerald Advisers LLC Acquires 177,129 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $42.60 Average Target Price from Analysts - Defense World
(COLL) Trading Report - Stock Traders Daily
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Collegium Pharmaceutical (COLL) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Allspring Global Investments Holdings LLC Has $3.08 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Assenagon Asset Management S.A. Sells 188,423 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? - MSN
Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards? - MSN
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment? - Simply Wall St
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewswire
Collegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to Buy at StockNews.com - MarketBeat
StockNews.com Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Buy - Defense World
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2024 Earnings Call Transcript - MSN
(COLL) Investment Report - Stock Traders Daily
Inspire Investing LLC Lowers Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Upgraded by StockNews.com - Defense World
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Short Interest Down 6.5% in September - MarketBeat
Sanctuary Advisors LLC Makes New Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Collegium Pharmaceutical (NASDAQ:COLL) Rating Increased to Strong-Buy at StockNews.com - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Receives Neutral Rating from Piper Sandler - Defense World
SG Americas Securities LLC Has $707,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Collegium Pharmaceutical (NASDAQ:COLL) Given "Neutral" Rating at Piper Sandler - MarketBeat
Collegium Pharmaceutical Inc [COLL] Records 50-Day SMA of $37.25 - Knox Daily
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? - Yahoo Finance
Market Update: Collegium Pharmaceutical Inc (COLL) Sees Negative Movement, Closing at 36.64 - The Dwinnex
Collegium Pharmaceutical And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
(COLL) Investment Analysis - Stock Traders Daily
Millennium Management LLC Has $9.79 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Keeping an Eye on Collegium Pharmaceutical Inc (COLL) After Insider Trading Activity - Knox Daily
70,964 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Acquired by Marshall Wace LLP - Defense World
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by ProShare Advisors LLC - Defense World
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Marshall Wace LLP Buys New Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Collegium Pharmaceutical stock hits all-time high of $41.04 By Investing.com - Investing.com Canada
Breakouts Boost These Three Stocks To All-Time Highs - Investor's Business Daily
Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 12-Month HighTime to Buy? - MarketBeat
Collegium Pharmaceutical stock hits all-time high of $41.04 - Investing.com
Axa S.A. Takes Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Collegium Pharmaceutical (NASDAQ:COLL) delivers shareholders solid 28% CAGR over 5 years, surging 5.1% in the last week alone - Simply Wall St
A new trading data show Collegium Pharmaceutical Inc (COLL) is showing positive returns. - SETE News
H.C. Wainwright’s latest rating for COLL stock - Knox Daily
Squarepoint Ops LLC Has $3.55 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Squarepoint Ops LLC Has $3.55 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Hsbc Holdings PLC Decreases Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Deerfield Management Company L.P. Series C Has $428,000 Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Maverick Capital Ltd. Has $1.28 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Should We Be Delighted With Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 46%? - Yahoo Finance
Collegium Pharmaceutical Inc Stock (COLL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):